Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Adaptive, Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous AMB-05X in Subjects With Tenosynovial Giant Cell Tumor

NCT04938180 is registered in ClinicalTrials.gov with AmMax Bio, Inc. as lead sponsor.

NCT NCT04938180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04938180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Adaptive, Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous AMB-05X in Subjects With Tenosynovial Giant Cell Tumor
Lead sponsor
AmMax Bio, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
September 16, 2021
Completion date
May 17, 2022
Enrollment
4 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pigmented villonodular synovitis, pvns - pigmented villonodular synovitis, tenosynovial giant cell tumor, tgct